氩氦刀冷冻消融联合PD1抑制剂+化疗治疗Ⅲb~Ⅳ期非小细胞肺癌的疗效评价  

Clinical efficacy of argon-helium cryoablation combined with PD1 inhibitor+chemotherapy in the treatment of stage Ⅲb-Ⅳ non-small cell lung cancer

作　　者：娄小飞[1] 杜可朴[2] 王猛[2] 李亚丹[2] 高飞[2] 高梦宇 杜雅冰[3] LOU Xiao-fei;DU Ke-pu;WANG Meng;LI Ya-dan;GAO Fei;GAO Meng-yu;DU Ya-bing(Department of Pharmacy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,CHINA;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,CHINA;Department of Radiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,CHINA)

机构地区：[1]郑州大学第一附属医院药学部,河南郑州450052 [2]郑州大学第一附属医院放射科,河南郑州450052 [3]郑州大学第一附属医院脑瘤内科,河南郑州450052

出　　处：《海南医学》2023年第16期2318-2322,共5页Hainan Medical Journal

基　　金：河南省科学技术协会青年人才托举工程(编号:2021HYTP058)。

摘　　要：目的评估氩氦刀冷冻消融联合抗程序性死亡蛋白1(PD1)抑制剂+化疗治疗Ⅲb~Ⅳ期非小细胞肺癌(NSCLC)的临床疗效。方法回顾性收集2017年5月至2020年5月郑州大学第一附属医院收治的54例经病理明确诊断不可手术切除的Ⅲb~Ⅳ期NSCLC肺癌患者的临床资料,根据治疗方法不同分为氩氦刀组29例和标准治疗组25例。化疗4个周期(3周为一个化疗周期)后,比较两组患者的近期客观缓解率(ORR)、无进展生存期(PFS)和无进展生存率。结果化疗4个周期后,氩氦刀组患者的ORR为75.86%,略高于标准治疗组的60.00%,但差异无统计学意义(P>0.05);随访3年,氩氦刀组患者的中位PFS为13.61个月,明显长于标准治疗组的9.72个月,差异具有统计学意义(P<0.05);氩氦刀组患者1年、2年、3年无进展生存率分别为82.76%、62.07%、13.79%,略高于标准治疗组的76.00%、56.00%、8.00%,但差异均无统计学意义(P>0.05)。结论氩氦刀消融联合PD1抑制剂+化疗用于治疗Ⅲb-Ⅳ期非小细胞肺癌,可在一定程度上提高患者的近期疗效和远期疗效,进一步提升患者的无进展生存期。Objective To evaluate the clinical efficacy of argon-helium cryoablation combined with anti-programmed death protein 1(PD1)inhibitor and chemotherapy in the treatment of stage Ⅲb~Ⅳ non-small cell lung cancer(NSCLC).Methods From May 2017 to May 2020,the data of 54 patients with stage Ⅲb~Ⅳ NSCLC who were confirmed by pathology as inoperable were retrospectively collected in the First Affiliated Hospital of Zhengzhou University.According to different treatment methods,they were divided into argon-helium knife group(29 cases)and standard treatment group(25 cases).After 4 cycles of chemotherapy(3 weeks as a chemotherapy cycle),short-term objective response rate(ORR),progression-free survival(PFS),and progression-free survival rate were compared between the two groups.Results After 4 cycles of chemotherapy,the ORR of the argon-helium knife group was 75.86%,which was slightly higher than 60.0%of the standard treatment group(P>0.05).After 3 years of follow-up,the PFS was 13.61 months in the argon-helium knife group,which was significantly longer than 9.72 months in the standard treatment group(P<0.05).The 1-year,2-year,and 3-year progression-free survival rates in the argon-helium knife group were 82.76%,62.07%,and 13.79%,respectively,which were slightly higher than 76.00%,56.00%,and 8.00% in the standard treatment group(P>0.05).Conclusion Argon-helium ablation combined with PD1 inhibitor and chemotherapy in the treatment of stage Ⅲb~Ⅳ non-small cell lung cancer can improve the short-term and long-term efficacy of patients to a certain extent,and further improve the progression-free survival of patients.

关 键 词：非小细胞肺癌 冷冻消融 抗程序性死亡蛋白1 客观缓解率 中位生存期 

分 类 号：R734.2[医药卫生—肿瘤]